TGF-Beta and Chronic Pancreatitis
Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated October 1, 2025
TGF-β and Chronic Pancreatitis
Transforming Growth Factor-Beta (TGF-β) is a multifunctional cytokine that plays a key role in chronic pancreatitis (CP), particularly in driving fibrosis and disease progression. Chronic pancreatitis is marked by inflammation, irreversible fibrosis, and loss of pancreatic function, and TGF-β is central to these processes.
Role of TGF-β in Chronic Pancreatitis
- Pancreatic Stellate Cell (PSC) Activation:
- TGF-β activates PSCs, turning them into myofibroblast-like cells that produce excessive extracellular matrix (ECM) proteins like collagen and fibronectin.
- Activated PSCs also secrete more TGF-β, creating a positive feedback loop that worsens fibrosis.
- ECM Deposition and Fibrosis:
- TGF-β promotes ECM accumulation by stimulating collagen production and inhibiting its degradation through tissue inhibitors of metalloproteinases (TIMPs).
- Epithelial-Mesenchymal Transition (EMT):
- TGF-β induces pancreatic epithelial cells to transform into mesenchymal cells, which further contribute to ECM production and tissue remodeling.
- Immune Modulation:
- TGF-β suppresses T-cell activity and promotes macrophage polarization into the pro-fibrotic M2 phenotype, perpetuating chronic inflammation.
Clinical Implications
- Elevated TGF-β levels correlate with disease severity in CP, making it a potential biomarker for fibrosis progression.
- Targeting TGF-β signaling is a promising therapeutic strategy to reduce fibrosis.
Therapeutic Approaches
- TGF-β Inhibitors: Drugs like fresolimumab block TGF-β activity.
- PSC Modulators: Agents like pirfenidone reduce PSC activation.
- Antioxidants: Compounds like N-acetylcysteine (NAC) attenuate oxidative stress, which amplifies TGF-β signaling.
Challenges
Systemic inhibition of TGF-β may cause side effects like impaired wound healing or immune suppression. Early intervention is crucial, as established fibrosis is difficult to reverse.
In summary, TGF-β is a central driver of fibrosis in chronic pancreatitis, making it a critical target for therapeutic strategies aimed at halting disease progression and improving patient outcomes.
